St. Jude Study Reveals Chronic Health Conditions Are Most Prevalent in Survivors of Pediatric Central Nervous System Cancers
A study by St. Jude has revealed that the extent of chronic health conditions in adult childhood cancer survivors is significantly more substantial than those in the general public. The results of this extensive research can be used to better inform future clinical guidelines, research investigations and health services planning for childhood cancer survivors.
NCI-COG Pediatric MATCH Trial Opens for Enrollment
A long-awaited and first-of-its-kind precision medicine clinical trial in childhood cancer is now open for enrollment. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) will explore the effectiveness of targeted therapies in children and adolescents with brain and other solid tumors.
Medulloblastoma Study Reveals New Subtypes of Malignant Childhood Brain Tumor
A new study published in Nature has uncovered a series of previously undiscovered medulloblastoma subtypes. The results of this latest research are expected to help advance new treatments for this highly malignant brain tumor that predominantly occurs in childhood.
Meet the Experts Brings Together Chicago Medical Community and Pediatric Brain Tumor Families to Learn and Network
To help answer families’ questions about childhood brain tumor treatments and the challenges that may follow, the Pediatric Brain Tumor Foundation’s Meet the Experts program brings together medical experts and parent experts across the country.
PBTF Grant Awardee to Run Neuro-Oncology Program at Rady Children’s Hospital
Rady Children’s Hospital - San Diego has named Dr. Robert Wechsler-Reya program director of the Joseph Clayes III Research Center for Neuro-Oncology and Genomics.
UC San Diego Bioengineers Developing Potential Blood Test for Early Cancer Detection
A new blood test being developed by bioengineers at the University of California San Diego could provide a way to diagnose cancer early on without invasive surgical procedures.
Early clinical trial results of dabrafenib positive for children with low-grade glioma
Early clinical trial results are positive for dabrafenib (Taflinar®), a candidate targeted therapy for children with low-grade glioma (LGG). The drug targets a mutation called BRAF V600E that occurs in several tumor types, including about 10 percent of LGGs. – Vector, Boston Children’s Hospital's science and clinical innovation blog
Cancer Moonshot report highlights new collaboration involving PBTF awardee, PNOC
The PBTF-funded Pacific Pediatric Neuro-Oncology Consortium (PNOC) and the Children’s Brain Tumor Tissue Consortium (CBTTC) announce a partnership that promises to radically pick up the pace of pediatric cancer research. Together with Seven Bridges, they have launched CAVATICA, a cloud-based platform that enables scientists around the globe to collaborate more effectively. This joint endeavor answers a call by the Cancer Moonshot initiative to de-silo data and enable rapid access and analysis of genomic and other types of data for discovery research.
Promising results of clinical study in pediatric low-grade glioma
Researchers report positive results for the first clinical study of dabrafenib, a targeted therapy, for pediatric low grade-grade glioma. Participants in this small study represent the subset of pediatric low-grade glioma patients whose tumors have a BRAF mutation.
Brain cancer now deadliest childhood cancer
Brain cancer has replaced leukemia as the No. 1 cancer killer of children and adolescents ages 1-19, according to a new report from the U.S. government. – CDC
Pediatric Cancer Dream Team continues to make progress in “immunogenomics”
In the fourth and final year of funding as the Stand Up To Cancer-St.Baldrick’s Pediatric Cancer Dream Team, leading researchers across North America continue to make progress in laboratory research and clinical trials for the development of new immunotherapies. – PR Newswire
Researchers engineer neural stem cells to create new laboratory model of medulloblastoma
Scientists have developed a new disease model that replicates how a type of medulloblastoma, called Group 3, develops. The model, based on the implantation of genetically engineered neural stem cells into mice, is proving useful for identifying potential therapeutic drug candidates. – National Cancer Institute.
FDA grants rare pediatric disease designation to ABT-414 for DIPG
The FDA has granted Rare Pediatric Disease Designation to AbbVie’s investigational compound, ABT-414 for the treatment of children with epidermal growth factor receptor (EGFR)-amplified diffuse intrinsic pontine glioma. DIPG is highly aggressive and is the second most common malignant pediatric brain tumor, affecting approximately 200 to 400 children each year in the United States.
US FDA grants orphan drug designation to Tocagen
The U.S. Food and Drug Administration has granted Tocagen orphan drug and Fast Track designations to their lead investigational compound, Toca 511 & Toca FC, for the treatment of recurrent high-grade glioma. The treatment kills tumor cells leading to activation of the immune system. – PR Newswire
Study focuses on carboplatin in pediatric low-grade glioma patients
A retrospective study of 266 patients has found that chemotherapy with carboplatin alone may be as effective as multiagent chemotherapy in children with inoperable low-grade gliomas. – Wiley Online Library
Cytomegalovirus and glioblastoma ― taking stock of the perplexing evidence to date
After examining 10 years of research, neurosurgeon Dr. Charles Cobbs gives his thoughts on the association and possible role of cytomegalovirus in the growth of glioblastoma, a highly aggressive brain tumor type. – BrainCancer.org
New protocol for MRIs in brain tumor clinical trials announced
The Jumpstarting Brain Tumor Drug Development Coalition has announced a new protocol for MRIs in brain tumor clinical trials. The protocol will allow doctors to better assess if a new treatment is effective. – Applied Clinical Trials
Study shows delaying chemoradiotherapy to permit molecular testing does not negatively affect outcomes
Based on a retrospective analysis, researchers found that delaying the initiation of chemoradiotherapy after surgery by 8 days (i.e., from 27 days to 35 days) to allow for testing of MGMT promoter status did not significantly affect patients’ survival in adults with glioblastoma. Rather, it was found that starting radiation therapy sooner than 24 days after surgery was found to have a negative impact. – BMC Cancer